J2351
HCPCSInj ocrelizumab 1mg hya-ocsq
Official HCPCS Level II long descriptor
Injection, ocrelizumab, 1 mg and hyaluronidase-ocsq
HCPCS Level II code J2351 is maintained by CMS and is active in the current quarterly release.
Short descriptor
Inj ocrelizumab 1mg hya-ocsq
Added to HCPCS: 2025-04-01
Nearby codes in J2
- J2315Naltrexone, depot form
- J2320Nandrolone decanoate 50 mg
- J2323Natalizumab injection
- J2325Nesiritide injection
- J2326Inj, nusinersen, 0.1mg
- J2327Inj risankizumab-rzaa 1 mg
- J2329Inj ublituximab-xiiy, 1 mg
- J2350Injection, ocrelizumab, 1 mg
- J2353Octreotide injection, depot
- J2354Octreotide inj, non-depot
- J2355Oprelvekin injection
- J2356Inj tezepelumab-ekko, 1mg
- J2357Omalizumab injection
- J2358Olanzapine long-acting inj
- J2359Inj. olanzapine, 0.5mg
- J2360Orphenadrine injection
Where this code sits
Krasyn AI Coder
Get code suggestions automatically as you type notes. Free for 50 analyses.
Install for Chrome — freeSource
HCPCS Level II July 2026 quarterly update. Centers for Medicare & Medicaid Services (CMS), “July 2026 Alpha-Numeric HCPCS File” (HCPC2026_JUL_ANWEB_06172026.txt). Download the original file from cms.gov. Public domain (US Government work). Descriptors, billable flags and instructional notes on this page are reproduced from that file without modification. Krasyn adds no clinical guidance.